<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Cardiol</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Cardiology</journal-title></journal-title-group><issn pub-type="ppub">2380-6583</issn><issn pub-type="epub">2380-6591</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11238071</article-id><article-id pub-id-type="pmcid-ver">PMC11238071.1</article-id><article-id pub-id-type="pmcaid">11238071</article-id><article-id pub-id-type="pmcaiid">11238071</article-id><article-id pub-id-type="pmid">38985488</article-id><article-id pub-id-type="doi">10.1001/jamacardio.2024.1712</article-id><article-id pub-id-type="publisher-id">hoi240035</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients</article-title><subtitle>A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Aspirin Dosing for CVD Prevention in Male and Female Patients</alt-title><alt-title alt-title-type="running-head">Aspirin Dosing for CVD Prevention in Male and Female Patients</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Benziger</surname><given-names initials="CP">Catherine P.</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stebbins</surname><given-names initials="A">Amanda</given-names></name><degrees>MS</degrees><xref rid="hoi240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wruck</surname><given-names initials="LM">Lisa M.</given-names></name><degrees>PhD</degrees><xref rid="hoi240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Effron</surname><given-names initials="MB">Mark B.</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marquis-Gravel</surname><given-names initials="G">Guillaume</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farrehi</surname><given-names initials="PM">Peter M.</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Girotra</surname><given-names initials="S">Saket</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="K">Kamal</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kripalani</surname><given-names initials="S">Sunil</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Munoz</surname><given-names initials="D">Daniel</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Polonsky</surname><given-names initials="TS">Tamar S.</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharlow</surname><given-names initials="A">Amber</given-names></name><degrees>MBA</degrees><xref rid="hoi240035aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Whittle</surname><given-names initials="J">Jeffrey</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="hoi240035aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harrington</surname><given-names initials="RA">Robert A.</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rothman</surname><given-names initials="RL">Russell L.</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hernandez</surname><given-names initials="AF">Adrian F.</given-names></name><degrees>MD</degrees><degrees>MHS</degrees><xref rid="hoi240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="WS">W. Schuyler</given-names></name><degrees>MD</degrees><xref rid="hoi240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="hoi240035aff1"><label>1</label>Heart and Vascular Center, Essentia Health, Duluth, Minnesota</aff><aff id="hoi240035aff2"><label>2</label>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina</aff><aff id="hoi240035aff3"><label>3</label>John Ochsner Heart and Vascular Institute, The University of Queensland&#8211;Ochsner Clinical School, New Orleans, Louisiana</aff><aff id="hoi240035aff4"><label>4</label>Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor</aff><aff id="hoi240035aff5"><label>5</label>Department of Internal Medicine, UT Southwestern, Dallas, Texas</aff><aff id="hoi240035aff6"><label>6</label>Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City</aff><aff id="hoi240035aff7"><label>7</label>Center for Clinical Quality and Implementation Research, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="hoi240035aff8"><label>8</label>Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee</aff><aff id="hoi240035aff9"><label>9</label>Section of Cardiology, Department of Medicine, University of Chicago Medicine, Chicago, Illinois</aff><aff id="hoi240035aff10"><label>10</label>Medidata Solutions, New York, New York</aff><aff id="hoi240035aff11"><label>11</label>Division of Medicine, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin</aff><aff id="hoi240035aff12"><label>12</label>Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> May 9, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> July 10, 2024. doi:<uri content-type="doi">10.1001/jamacardio.2024.1712</uri></p><corresp id="hoi240035cor1"><bold>Corresponding Author:</bold> Catherine Benziger, Heart and Vascular Center, Essentia Health, 402 E 2nd St, Duluth, MN 55805 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="catherine.benziger@essentiahealth.org">catherine.benziger@essentiahealth.org</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Jones had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Benziger, Marquis-Gravel, Girotra, Gupta, Harrington, Rothman, Hernandez, Jones.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Benziger, Stebbins, Wruck, Effron, Marquis-Gravel, Farrehi, Girotra, Kripalani, Mu&#241;oz, Polonsky, Sharlow, Whittle, Harrington, Rothman, Hernandez, Jones.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Benziger, Stebbins.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Benziger, Wruck, Effron, Marquis-Gravel, Farrehi, Girotra, Gupta, Kripalani, Mu&#241;oz, Polonsky, Sharlow, Whittle, Harrington, Rothman, Hernandez, Jones.</p><p><italic toggle="yes">Statistical analysis:</italic> Benziger, Stebbins, Wruck, Marquis-Gravel.</p><p><italic toggle="yes">Obtained funding:</italic> Hernandez, Jones.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Benziger, Marquis-Gravel, Farrehi, Sharlow, Whittle, Harrington, Hernandez, Jones.</p><p><italic toggle="yes">Supervision:</italic> Benziger, Kripalani, Mu&#241;oz, Polonsky, Whittle, Harrington, Rothman, Jones.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Wruck reported receiving grants from Patient-Centered Outcomes Research Institute (PCORI) and Bayer during the conduct of the study. Dr Effron reported receiving steering committee fees PCORI during the conduct of the study. Dr Marquis-Gravel reported receiving grants and personal fees from Bayer and personal fees from Novartis, Boston Scientific, HLS Therapeutics, Pendopharm, and JAMP Pharma outside the submitted work. Dr Girotra reported receiving grants from the National Heart, Lung, and Blood Institute and a stipend from the American Heart Association for editorial work during the conduct of the study. Dr Kripalani reported receiving personal fees from Gilead Sciences and grants from Esperion Therapeutics outside the submitted work. Dr Whittle reported receiving grants from PCORI during the conduct of the study. Dr Harrington reported receiving grants from Janssen, advisory fees from Basking Biosciences, and serving on the board of directors for Cytokinetics and the American Heart Association. Dr Rothman reported receiving grants from PCORI during the conduct of the study. Dr Hernandez reported receiving grants from AstraZeneca, Bayer, Bristol Myers Squibb, Merck, and Novo Nordisk outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported through award ASP-1502-27029 from the <funding-source rid="sp1">Patient-Centered Outcomes Research Institute (PCORI)</funding-source> with additional funding provided by <funding-source rid="sp2">Bayer</funding-source>.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors, or its Methodology Committee.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-HOI240035-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p><p><bold>Additional Contributions:</bold> We thank Brooke Walker, MS, Duke Clinical Research Institute, who provided editorial support. Ms Walker did not receive compensation for her contributions, apart from her employment at the institution in which this study was conducted.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-07-10T10:00"><day>10</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2024</year></pub-date><volume>9</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">466585</issue-id><fpage>808</fpage><lpage>816</lpage><history><date date-type="received"><day>3</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-10 00:25:52.797"><day>10</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamacardiol-e241712.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamacardiol-e241712.pdf">jamacardiol-e241712.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/cardiology/fullarticle/10.1001/jamacardio.2024.1712"/><abstract abstract-type="teaser" specific-use="electronic"><p>This secondary analysis of the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical trial investigates if there are sex-specific differences in the safety and effectiveness of 2 aspirin doses for the secondary prevention of atherosclerotic cardiovascular disease (CVD).</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-hoi240035-1"><title>Question</title><p>Are there sex-specific differences in the safety and effectiveness of 2 aspirin doses for the secondary prevention of atherosclerotic cardiovascular disease?</p></sec><sec id="ab-hoi240035-2"><title>Findings</title><p>Of 15&#8201;076 patients in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial, female patients randomized to receive aspirin, 81 mg, were younger, less likely to self-report White race, and had more comorbidities than males. No differences were observed in the primary effectiveness end point between aspirin doses in females and males, and no significant interaction was observed between the sexes for safety between the 2 aspirin doses.</p></sec><sec id="ab-hoi240035-3"><title>Meaning</title><p>Results of this randomized clinical trial revealed that in both males and females with atherosclerotic cardiovascular disease, no significant differences in effectiveness and safety were observed between 81-mg and 325-mg aspirin doses administered daily.</p></sec></abstract><abstract><sec id="ab-hoi240035-4"><title>Importance</title><p>Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical trial. However, it is unknown whether differences by sex exist in the safety and effectiveness of the different aspirin doses.</p></sec><sec id="ab-hoi240035-5"><title>Objective</title><p>To evaluate sex-specific differences in the safety and effectiveness of 2 aspirin doses in the ADAPTAPLE trial.</p></sec><sec id="ab-hoi240035-6"><title>Design, Setting, and Participants</title><p>The ADAPTABLE study was an open-label, pragmatic, randomized clinical trial that randomly assigned participants with chronic, stable ASCVD to 81 mg vs 325 mg of aspirin daily. Using Cox proportional-hazard models, male and female participants were compared for outcomes. In addition, it was assessed whether sex was an effect modifier in the association between aspirin dose and outcomes. The ADAPTABLE trial was conducted at 40 medical centers and 1 health plan. Eligible patients were 18 years and older and had established ASCVD. Study data were analyzed from December 2021 to March 2024.</p></sec><sec id="ab-hoi240035-7"><title>Interventions</title><p>Patients received 81 mg or 325 mg of aspirin daily for the secondary prevention of ASCVD.</p></sec><sec id="ab-hoi240035-8"><title>Main Outcomes and Measures</title><p>The primary effectiveness outcomes included all-cause death and hospitalization for myocardial infarction (MI) or stroke. The primary safety outcome was hospitalization for major bleeding requiring transfusion.</p></sec><sec id="ab-hoi240035-9"><title>Results</title><p>A total of 15&#8201;076 patients (median [IQR] age, 67.6 [60.7-73.6] years; 10&#8201;352 male [68.7%]) were followed up for a median (IQR) of 26.2 (19.0-34.9) months. Overall, 4724 (31.3%) were female, and 2307 of the female participants (48.8%) received aspirin 81 mg. Compared with males, female participants were younger (median [IQR] age, 66.3 [59.4-72.6] years vs 68.2 (61.4-73.9) years, less likely to self-report White race (3426 [72.5%] vs 8564 [82.7%]), more likely to smoke (564 [12.9%] vs 818 [8.4%]), and more likely to have a history of peripheral arterial disease (1179 [25.7%] vs 2314 [23.0%]). The primary effectiveness outcome of all-cause death and hospitalization for MI or stroke occurred in 379 female participants (8.1%) and 780 male participants (7.1%). There was no significant interaction by sex for the primary effectiveness end point between the 2 aspirin doses (female adjusted hazard ratio [aHR], 1.01; 95% CI, 0.82-1.26 and male aHR, 1.06; 95% CI, 0.91-1.23; <italic toggle="yes">P</italic> interaction term for sex&#8201;=&#8201;.74). During the trial, female participants had fewer revascularization procedures (237 [5.0%] vs 680 [6.6%]; aHR, 0.79; 95% CI, 0.68-0.92; <italic toggle="yes">P</italic>&#8201;=&#8201;.002) but had a higher risk of hospitalization for stroke (aHR, 1.72; 95% CI, 1.27-2.33; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). Among female participants, there was a slightly higher rate of bleeding in the 81-mg aspirin cohort compared with the 325-mg cohort (20 [0.83%] vs 13 [0.52%]; aHR, 2.21; 95% CI, 1.04-4.70; <italic toggle="yes">P</italic> interaction term for sex&#8201;=&#8201;.07). There were no significant differences between female and male participants regarding aspirin dose adherence.</p></sec><sec id="ab-hoi240035-10"><title>Conclusions and Relevance</title><p>In this secondary analysis of the ADAPTABLE trial, there were no significant sex-specific differences in the effectiveness and safety of 2 aspirin doses for secondary prevention of ASCVD events.</p></sec><sec id="ab-hoi240035-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02697916" ext-link-type="uri">NCT02697916</ext-link></p></sec></abstract><funding-group><award-group><funding-source id="sp1">Patient-Centered Outcomes Research Institute (PCORI)</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp2">Bayer</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>